ReviewFrontiers in bioengineering and biotechnology2023
Exploring the therapeutic potential of recombinant human lysozyme: a review on wound management system with antibacterial.
Review in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Resource-efficient use of industrial residue for multifunctional cacao nanofibers.Frontiers in bioengineering and biotechnology · 2026Article
- Lysozyme-dequalinium encapsulation in a Zn-Fe LDH-chia seed matrix for enhanced antimicrobial dental therapeutics.RSC advances · 2025Article
- Review
- Research Progress in Medical Biomaterials for Bone Infections.Journal of functional biomaterials · 2025Review
- Biocompatible OFETs for Selective and Real-Time Bacterial Detection Using BSA and Lysozyme Layers.ACS applied bio materials · 2025Article
- Nano-Biomimetic Fibronectin/Lysostaphin-Co-Loaded Silk Fibroin Dressing Accelerates Full-Thickness Wound Healing via ECM-Mimicking Microarchitecture and Dual-Function Modulation.International journal of nanomedicine · 2025Article
- A novel lysin Ply691 exhibits potent bactericidal activity againstFrontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysozyme, a natural antibacterial enzyme protein, possesses the ability to dissolve the cell walls of Gram-positive bacteria, demonstrating broad-spectrum antibacterial activity. Despite its significant potential in treating wound infections and promoting wound healing, its widespread clinical application has yet to be realized. Current research is primarily focused on carrier-based delivery systems for lysozyme. In this review, we discuss four delivery systems that can be employed for lysozyme in wound healing treatment, specifically hydrogels, nanofilms, electrospun fibrous membranes, and modified-lysozyme composite systems. These systems not only enhance the stability of lysozyme but also enable its controlled and sustained release at wound sites, potentially overcoming some of the challenges associated with its direct application. Lastly, we delve into the perspectives and challenges related to the use of these delivery systems, hoping to spur further research and innovation in this promising field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.